CAMP NASDAQ
CAMP4 Therapeutics Corporation
1W: +0.5%
1M: -3.5%
3M: +1.4%
YTD: -26.7%
1Y: +97.3%
$4.51
+0.11 (+2.50%)
Weekly Expected Move ±7.2%
$4
$4
$4
$5
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$95.8M
52W Range1.305-7.75
Volume76,185
Avg Volume187,220
Beta0.04
Dividend—
Analyst Ratings
Company Info
CEOJoshua Mandel-Brehm
Employees55
SectorHealthcare
IndustryBiotechnology
IPO Date2024-10-11
Websitecamp4tx.com
One Kendall Square Bldg 1400 West, 3rd Floor
Cambridge, MA 02139
US
Cambridge, MA 02139
US
617-651-8867
About CAMP4 Therapeutics Corporation
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
Latest News
Camp4 Therapeutics GAAP EPS of -$0.32 misses by $0.11
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Sees Large Decrease in Short Interest
Brokerages Set CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Price Target at $9.00
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Tardiff Daniel | A-Award | 170,000 | $4.46 | 2026-04-01 |
| Maricich Yuri | A-Award | 215,000 | $4.46 | 2026-04-01 |
| Gold Kelly | A-Award | 215,000 | $4.46 | 2026-04-01 |
| Mandel-Brehm Josh | A-Award | 580,000 | $4.46 | 2026-04-01 |
| MacLean Michael F | A-Award | 56,000 | $4.46 | 2026-04-01 |